Novo Nordisk A/S (NYSE:NVO) – Stock analysts at Jefferies Group dropped their FY2019 EPS estimates for Novo Nordisk A/S in a note issued to investors on Thursday, according to Zacks Investment Research. Jefferies Group analyst J. Holford now forecasts that the company will earn $2.52 per share for the year, down from their prior estimate of $2.64. Jefferies Group also issued estimates for Novo Nordisk A/S’s FY2020 earnings at $2.79 EPS and FY2021 earnings at $3.14 EPS.
Several other analysts also recently weighed in on the stock. Zacks Investment Research downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Friday, October 27th. BNP Paribas downgraded shares of Novo Nordisk A/S from an “outperform” rating to a “neutral” rating in a research report on Monday, September 25th. Bank of America Corporation raised shares of Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a research report on Wednesday, September 6th. Finally, BidaskClub raised shares of Novo Nordisk A/S from a “sell” rating to a “hold” rating in a research report on Saturday, August 12th. Three equities research analysts have rated the stock with a sell rating, six have issued a hold rating and one has given a buy rating to the company. The company has an average rating of “Hold” and an average target price of $55.00.
Shares of Novo Nordisk A/S (NVO) traded down $0.15 during trading on Monday, hitting $49.76. 895,100 shares of the stock were exchanged, compared to its average volume of 2,158,519. Novo Nordisk A/S has a 52-week low of $30.89 and a 52-week high of $50.95. The stock has a market cap of $97,260.00, a P/E ratio of 21.80, a P/E/G ratio of 2.98 and a beta of 0.65.
In other news, insider Eric S. Sprott bought 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 8th. The stock was purchased at an average cost of $8.34 per share, for a total transaction of $417,000.00.
A number of large investors have recently bought and sold shares of the business. Kalos Management Inc. raised its position in Novo Nordisk A/S by 3.1% during the third quarter. Kalos Management Inc. now owns 69,221 shares of the company’s stock worth $3,333,000 after acquiring an additional 2,080 shares during the period. Point72 Asset Management L.P. acquired a new position in Novo Nordisk A/S during the third quarter worth $7,194,000. Foyston Gordon & Payne Inc raised its position in Novo Nordisk A/S by 49.7% during the third quarter. Foyston Gordon & Payne Inc now owns 171,472 shares of the company’s stock worth $8,256,000 after acquiring an additional 56,941 shares during the period. Hansberger Growth Investors LP raised its position in Novo Nordisk A/S by 11.5% during the third quarter. Hansberger Growth Investors LP now owns 44,674 shares of the company’s stock worth $2,151,000 after acquiring an additional 4,624 shares during the period. Finally, Zions Bancorporation raised its position in Novo Nordisk A/S by 677.1% during the third quarter. Zions Bancorporation now owns 2,852 shares of the company’s stock worth $137,000 after acquiring an additional 2,485 shares during the period. Institutional investors own 6.01% of the company’s stock.
About Novo Nordisk A/S
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.